Treatment of chronic obstructive pulmonary disease (COPD) patients with Spiolto Respimat (tiotropium/olodaterol) reduced the rate of moderate-to-severe exacerbations, compared to Spiriva Respimat (tiotropium bromide), in a Phase 3 clinical trial, according to Boehringer Ingelheim, the manufacturer of both therapies. The results were published in the journal The Lancet Respiratory Medicine,…
A dossier assessment developed by the German Institute for Quality and Efficiency in Health Care (IQWiG) examined the added benefit of the fixed-dose combination therapy tiotropium plus olodaterol (Spiolto Respimat), approved this year for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. The study compared tiotropium/olodaterol…
Data analysis of three trials, OTEMTO® 1 and 2 and ENERGITO®, provided new evidence that Spiolto® Respimat® (Boehringer Ingelheim) improves the quality of life for chronic obstructive pulmonary disease (COPD) patients in maintenance therapy, and it offers a greater overall patient well-being and lung function in comparison to commonly…
Boehringer Ingelheim recently released a report on the company’s findings from the Phase IIIb OTEMTO 1 (NCT01964352) & 2 (NCT02006732) clinical trials, which are testing combination treatment Spiolto® Respimat® (tiotropium/olodaterol) for patients with chronic obstructive pulmonary disease (COPD). The update is published in the…
Boehringer Ingelheim recently announced regulatory authority approvals in the first European countries for its Spiolto Respimat (tiotropium/olodaterol) therapy. The drug is a maintenance bronchodilator treatment designed to ease symptoms in adult patients suffering from chronic obstructive pulmonary disease (COPD). Boehringer did not stipulate in its press release which European countries are…
Get regular updates to your inbox.